Molecular Insight into Substrate Recognition and Catalysis of Baeyer-Villiger Monooxygenase MtmOIV, the Key Frame-modifying Enzyme in the Biosynthesis of Anticancer Agent Mithramycin

Overview

Journal ACS Chem Biol

Publisher American Chemical Society

Specialties Biochemistry
Biology

Date 2013 Sep 3

PMID 23992662

Citations 15

Authors

Mary A Bosserman

Theresa Downey

Nicholas Noinaj

Susan K Buchanan

Jurgen Rohr

Affiliations

Soon will be listed here.

Abstract

Baeyer-Villiger monooxygenases (BVMOs) have been shown to play key roles for the biosynthesis of important natural products. MtmOIV, a homodimeric FAD- and NADPH-dependent BVMO, catalyzes the key frame-modifying steps of the mithramycin biosynthetic pathway, including an oxidative C-C bond cleavage, by converting its natural substrate premithramycin B into mithramycin DK, the immediate precursor of mithramycin. The drastically improved protein structure of MtmOIV along with the high-resolution structure of MtmOIV in complex with its natural substrate premithramycin B are reported here, revealing previously undetected key residues that are important for substrate recognition and catalysis. Kinetic analyses of selected mutants allowed us to probe the substrate binding pocket of MtmOIV and also to discover the putative NADPH binding site. This is the first substrate-bound structure of MtmOIV providing new insights into substrate recognition and catalysis, which paves the way for the future design of a tailored enzyme for the chemo-enzymatic preparation of novel mithramycin analogues.

Citing Articles

Unexpected enzyme-catalysed [4+2] cycloaddition and rearrangement in polyether antibiotic biosynthesis.

Little R, Paiva F, Jenkins R, Hong H, Sun Y, Demydchuk Y Nat Catal. 2024; 2(11):1045-1054.

PMID: 39659772 PMC: 7617221. DOI: 10.1038/s41929-019-0351-2.

A flavin-monooxygenase catalyzing oxepinone formation and the complete biosynthesis of vibralactone.

Feng K, Zhang Y, Zhang M, Yang Y, Liu J, Pan L Nat Commun. 2023; 14(1):3436.

PMID: 37301868 PMC: 10257657. DOI: 10.1038/s41467-023-39108-x.

Three Rings to Rule Them All: How Versatile Flavoenzymes Orchestrate the Structural Diversification of Natural Products.

Toplak M, Teufel R Biochemistry. 2021; 61(2):47-56.

PMID: 34962769 PMC: 8772269. DOI: 10.1021/acs.biochem.1c00763.

Catalytic Control of Spiroketal Formation in Rubromycin Polyketide Biosynthesis.

Toplak M, Saleem-Batcha R, Piel J, Teufel R Angew Chem Int Ed Engl. 2021; 60(52):26960-26970.

PMID: 34652045 PMC: 9299503. DOI: 10.1002/anie.202109384.

Enzymatic spiroketal formation via oxidative rearrangement of pentangular polyketides.

Frensch B, Lechtenberg T, Kather M, Yunt Z, Betschart M, Kammerer B Nat Commun. 2021; 12(1):1431.

PMID: 33664266 PMC: 7933358. DOI: 10.1038/s41467-021-21432-9.

References

Wang G, Pahari P, Kharel M, Chen J, Zhu H, Van Lanen S . Cooperation of two bifunctional enzymes in the biosynthesis and attachment of deoxysugars of the antitumor antibiotic mithramycin. Angew Chem Int Ed Engl. 2012; 51(42):10638-42. PMC: 3821964. DOI: 10.1002/anie.201205414. View

Zojer N, Keck A, Pecherstorfer M . Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf. 1999; 21(5):389-406. DOI: 10.2165/00002018-199921050-00004. View

Leadbeater C, McIver L, Campopiano D, Webster S, Baxter R, Kelly S . Probing the NADPH-binding site of Escherichia coli flavodoxin oxidoreductase. Biochem J. 2000; 352 Pt 2:257-66. PMC: 1221455. View

Hadjipavlou A, Gaitanis L, Katonis P, Lander P . Paget's disease of the spine and its management. Eur Spine J. 2001; 10(5):370-84. PMC: 3611523. DOI: 10.1007/s005860100329. View

Emsley P, Cowtan K . Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004; 60(Pt 12 Pt 1):2126-32. DOI: 10.1107/S0907444904019158. View

Adams P, Grosse-Kunstleve R, Hung L, Ioerger T, McCoy A, Moriarty N . PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr. 2002; 58(Pt 11):1948-54. DOI: 10.1107/s0907444902016657. View

Lombo F, Menendez N, Salas J, Mendez C . The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivatives. Appl Microbiol Biotechnol. 2006; 73(1):1-14. DOI: 10.1007/s00253-006-0511-6. View

Cosconati S, Forli S, Perryman A, Harris R, Goodsell D, Olson A . Virtual Screening with AutoDock: Theory and Practice. Expert Opin Drug Discov. 2011; 5(6):597-607. PMC: 3083070. DOI: 10.1517/17460441.2010.484460. View

Philmus B, Abdelwahed S, Williams H, Fenwick M, Ealick S, Begley T . Identification of the product of toxoflavin lyase: degradation via a Baeyer-Villiger oxidation. J Am Chem Soc. 2012; 134(11):5326-30. PMC: 3332044. DOI: 10.1021/ja211759n. View

10.

Koma D, Sakashita Y, Kubota K, Fujii Y, Hasumi F, Chung S . Degradation pathways of cyclic alkanes in Rhodococcus sp. NDKK48. Appl Microbiol Biotechnol. 2004; 66(1):92-9. DOI: 10.1007/s00253-004-1623-5. View

11.

Nunez L, Nybo S, Gonzalez-Sabin J, Perez M, Menendez N, Brana A . A novel mithramycin analogue with high antitumor activity and less toxicity generated by combinatorial biosynthesis. J Med Chem. 2012; 55(12):5813-25. PMC: 3395220. DOI: 10.1021/jm300234t. View

12.

Winn M, Ballard C, Cowtan K, Dodson E, Emsley P, Evans P . Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr. 2011; 67(Pt 4):235-42. PMC: 3069738. DOI: 10.1107/S0907444910045749. View

13.

Yachnin B, Sprules T, McEvoy M, Lau P, Berghuis A . The substrate-bound crystal structure of a Baeyer-Villiger monooxygenase exhibits a Criegee-like conformation. J Am Chem Soc. 2012; 134(18):7788-95. PMC: 3349289. DOI: 10.1021/ja211876p. View

14.

Torres Pazmino D, Baas B, Janssen D, Fraaije M . Kinetic mechanism of phenylacetone monooxygenase from Thermobifida fusca. Biochemistry. 2008; 47(13):4082-93. DOI: 10.1021/bi702296k. View

15.

Norgan A, Coffman P, Kocher J, Katzmann D, Sosa C . Multilevel Parallelization of AutoDock 4.2. J Cheminform. 2011; 3(1):12. PMC: 3098179. DOI: 10.1186/1758-2946-3-12. View

16.

Kiang D, LOKEN M, Kennedy B . Mechanism of the hypocalcemic effect of mithramycin. J Clin Endocrinol Metab. 1979; 48(2):341-4. DOI: 10.1210/jcem-48-2-341. View

17.

Gibson M, Nur-E-Alam M, Lipata F, Oliveira M, Rohr J . Characterization of kinetics and products of the Baeyer-Villiger oxygenase MtmOIV, the key enzyme of the biosynthetic pathway toward the natural product anticancer drug mithramycin from Streptomyces argillaceus. J Am Chem Soc. 2005; 127(50):17594-5. DOI: 10.1021/ja055750t. View

18.

Otwinowski Z, Minor W . Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997; 276:307-26. DOI: 10.1016/S0076-6879(97)76066-X. View

19.

Wang C, Gibson M, Rohr J, Oliveira M . Crystallization and X-ray diffraction properties of Baeyer-Villiger monooxygenase MtmOIV from the mithramycin biosynthetic pathway in Streptomyces argillaceus. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006; 61(Pt 11):1023-6. PMC: 1978135. DOI: 10.1107/S1744309105033221. View

20.

Lee T, Jung E, Lee J, Kim S, Park J, Choi K . Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol Cancer Ther. 2006; 5(11):2737-46. DOI: 10.1158/1535-7163.MCT-06-0426. View